New spectrofluorimetric and spectrophotometric methods for the determination of the analgesic drug, nalbuphine in pharmaceutical and biological fluids

Construction of novel potentiometric sensors modified with biogenically synthesized metal oxide nanoparticles for sensitive detection of the opioid agonist-antagonist nalbuphine hydrochloride in its injection

Novel and sensitive potentiometric sensors were described for the assay of nalbuphine HCl (NBP) in authentic powder and injection samples. The developed sensors were modified with alumina nanoparticles (Al2O3NPs) and copper oxide nanoparticles (CuONPs). The nanoscale materials were synthesized using the extract of Salvia officinalis leaves in an environmentally friendly manner. The synthesized metal oxides were fully confirmed by various analytical techniques. Scanning electron microscope confirmed the morphology of nanosized materials with even distribution and particle size of 55.07 ± 4.15 and 59.48 ± 4.50 nm for Al2O3NPs and CuONPs, respectively. The modified sensors were prepared in three different steps. Nalbuphine hydrochloride was mixed with phosphomolybdic acid to prepare the sensor material nalbuphine phosphomolybdate (NBP-PM). It was then mixed with polyvinyl chloride in the presence of o-nitrophenyl ether and metal oxide nanoparticles to form the membrane matrix. Finally, a copper wire was coated with the sensing material. Excellent potentials of 1.0 × 10-8-1.0 × 10-2 and 1.0 × 10-9-1.0 × 10-2 mol L-1 were measured with lower assay limits of 4.8 × 10-9 and 5.0 × 10-10 mol L-1. The average detection % were 99.28 ± 0.58% and 99.52 ± 0.28% for NBP-PM-Al2O3NPs and NBP-PM-CuONPs, correspondingly. The suitability of the described sensors was investigated in terms of various validation criteria, and the modified sensors exposed excellent applicability and insurance for the quantification of nalbuphine hydrochloride in its bulk samples and injections compared with another standard sensor. It is obvious that the developed NBP-PM-Al2O3NPs and NBP-PM-CuONPs will serve as suitable sensors for the determination of NBP.

Eco-friendly fluorimetric approaches for the simultaneous estimation of the co-administered ternary mixture: etoposide, moxifloxacin and nalbuphine

Antineoplastic drugs, etoposide (ETO), are widely used in leukaemia. A patient with leukaemia has a relative infection with pneumonia treated by fluoroquinolones as moxifloxacin HCL (MOX). Because opioid analgesic as nalbuphine HCL (NAL) does not have a ceiling dose, it is used to manage the distasteful sensory in leukaemia. Consequently, green methods for synchronous spectrofluorimetric quantification of a ternary mixture of ETO, MOX and NAL were developed. The first approach relies simply on the estimation of MOX at 371 nm by conventional synchronous fluorimetric technique (Δλ of 60 nm). The second approach depends on applying the first derivative synchronous fluorimetric technique (Δλ of 60 nm) for simultaneous estimation of ETO and NAL at 257 and 273 nm, respectively. A good linear correlation was obtained in the ranges of 0.04-0.40, 0.10-1.00 and 0.50-5.00 µg ml-1 for MOX, ETO and NAL, respectively. Moreover, the proposed approaches were successfully applied for the estimation of the studied drugs in the pharmaceutical dosage forms. Additionally, the synchronous assessment of ETO, MOX and NAL in the spiked human urine was successfully attained by the facile protein precipitation technique. The mean % recoveries in spiked human urine were 99.49, 98.07 and 98.48 for MOX, ETO and NAL, respectively.

Determination of Nalbuphine Hydrochloride in Pharmaceutical Formulations Using Diperiodatoargentate(III)-Rhodamine-B Chemiluminescence System by Flow Injection Analysis

A novel method for the analysis of nalbuphine hydrochloride (NAL) is reported based on its enhancement effect on a diperiodatoargentate(III)-rhodamine-B (Ag(III) complex-Rh-B) chemiluminescence (CL) system in an aqueous sulfuric acid medium using flow-injection analysis (FIA). The optimal conditions of the CL reaction were: sulfuric acid, 10^-2 M; Ag(III) complex, 2.0 × 10^-4 M; Rh-B, 2.0 × 10^-5 M; Brij-35, 0.01%; sample loop volume, 300 μL; and flow rate, 3.0 mL/min/stream. The limit of detection (LOD) and limit of quantification (LOQ) were 0.001 and 0.003 mg/L (S/N = 3 and 10); linear calibration range, 5 × 10^-3 - 5.0 mg/L (R² = 0.9999) and injection throughput, 150/h. The relative standard deviation (RSD) was from 0.8 - 3.2% over the range studied. The suggested technique was applied for the determination of NAL in pharmaceutical injections, compared with a reported spectrophotometric method, and obtained results were found to be satisfactory. Based on spectrophotometric studies, the most probable mechanism of the CL reaction has been briefly described and drawn schematically.

Conventional and first derivative synchronous spectrofluorimetric methods for the simultaneous determination of cisatracurium and nalbuphine in biological fluids

Cisatracurium besylate has been determined by fast and highly sensitive spectrofluorimetric method based on measuring the fluorescence intensity of its methanolic solution at 312 nm after excitation at 230 nm (Method I). The linearity occurred over the concentration range of 10.0-130.0 ng/mL with detection limit of 1.07 ng/mL. The method was further extended for the determination of the studied drug in spiked human plasma with good percentage recoveries (97.43-103.50%). Cisatracurium is co-administered with nalbuphine during surgery. The simultaneous determination of both drugs was based on synchronous spectrofluorimetric technique. First derivative synchronous spectrofluorimetric amplitude was measured in methanol at Δ λ = 60 nm and each drug could be estimated at the zero crossing point of the other. Hence, cisatracurium could be measured at 284.6 nm while nalbuphine at 276.3 nm (Method II). The method was linear over the ranges of 50.0-750.0 ng/mL and 0.5-7.0 μg/mL with the detection limits of 2.16 ng/mL and 0.04 μg/mL for cisatracurium and nalbuphine, respectively. The method was further extended for the simultaneous determination of both drugs in spiked human urine with mean percentage recoveries of 99.99 ± 2.06 and 99.53 ± 6.17 for cisatracurium and nalbuphine, respectively. Both methods were validated in agreement with Guidelines adopted by International Council of Harmonization (ICH).

New spectrophotometric/chemometric assisted methods for the simultaneous determination of imatinib, gemifloxacin, nalbuphine and naproxen in pharmaceutical formulations and human urine

In this paper, novel univariate and multivariate regression methods along with model-updating technique were developed and validated for the simultaneous determination of quaternary mixture of imatinib (IMB), gemifloxacin (GMI), nalbuphine (NLP) and naproxen (NAP). The univariate method is extended derivative ratio (EDR) which depends on measuring every drug in the quaternary mixture by using a ternary mixture of the other three drugs as divisor. Peak amplitudes were measured at 294nm, 250nm, 283nm and 239nm within linear concentration ranges of 4.0-17.0, 3.0-15.0, 4.0-80.0 and 1.0-6.0μgmL^-1 for IMB, GMI, NLP and NAB, respectively. Multivariate methods adopted are partial least squares (PLS) in original and derivative mode. These models were constructed for simultaneous determination of the studied drugs in the ranges of 4.0-8.0, 3.0-11.0, 10.0-18.0 and 1.0-3.0μgmL^-1 for IMB, GMI, NLP and NAB, respectively, by using eighteen mixtures as a calibration set and seven mixtures as a validation set. The root mean square error of predication (RMSEP) were 0.09 and 0.06 for IMB, 0.14 and 0.13 for GMI, 0.07 and 0.02 for NLP and 0.64 and 0.27 for NAP by PLS in original and derivative mode, respectively. Both models were successfully applied for analysis of IMB, GMI, NLP and NAP in their dosage forms. Updated PLS in derivative mode and EDR were applied for determination of the studied drugs in spiked human urine. The obtained results were statistically compared with those obtained by the reported methods giving a conclusion that there is no significant difference regarding accuracy and precision.